BBH
VanEck Biotech ETF
VanEck Vectors Biotech ETF is an exchange-traded fund incorporated in the USA. The Fund seeks to track the performance of the US Listed Biotech 25 Index.
US
EQUITY
Passive
MANAGEMENT STYLE
$ 353.7 M
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Dec 20, 2011 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| GILEAD SCIENCES INC | 14.1 % |
| AMGEN INC | 13.9 % |
| VERTEX PHARMACEUTICALS INC | 8.1 % |
| ARGENX SE ADR | 6.0 % |
| REGENERON PHARMACEUTICALS | 6.0 % |
| REVOLUTION MEDICINES, INC. | 4.6 % |
| IQVIA HOLDINGS INC | 4.6 % |
| NATERA INC | 4.4 % |
| BIOGEN IDEC INC | 4.0 % |
| ALNYLAM PHARMACEUTICALS INC | 3.7 % |
Constituent Breakdown
| Number of holdings | 26 |
| Herfindahl-Hirschman Index | 708 |
| Wgt avg mkt cap (mns) | $86,570 |
| Large cap (>$10bn) | 94.2% |
| Mid cap ($2-10bn) | 4.8% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 96.6% |
| Emerging mkts. | 3.5% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 85.8 % |
 |
NETHERLANDS | 7.1 % |
 |
CHINA | 3.1 % |
 |
GERMANY | 2.3 % |
 |
IRELAND | 1.6 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -0.3% | 27.2% | 7.1% | 6.9% | 0.5% | 5.5% | -- | 12.3% |
| Dividend Yield | 0.0% | 0.6% | 0.7% | 0.6% | 0.5% | 0.5% | -- | 0.7% |
| Total Returns | -0.3% | 27.8% | 7.8% | 7.5% | 1.0% | 6.0% | -- | 13.0% | Ann. Volatility | 20.7% | 18.8% | 20.1% | 18.8% | 21.5% | 22.2% | -- | 22.9% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.77 | 23% |
| MSCI EAFE | 0.67 | 29% |
| MSCI Emg Mkts | 0.40 | 17% |
Liquidity Measures
| Avg. volume (000) | 5 |
| ADV traded (mns) | $1 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.13% |
Technical Indicators
| 30d moving avg. (EMA) | $185.89 |
| Relative strength (RSI) | 51 |
| MACD/Signal | -0.28/-0.89 |
| Bollinger Bands (Upper/Lower) | $190.04/$180.09 |
| Short interest (% of AUM) | 0.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. BBH |
Expenses vs. BBH |
ALTAR Score™ vs. BBH |
|---|---|---|---|---|
| IBB | iShares Biotechnology ETF | 59.5% | +10 bp | -5.4% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 49.8% | -16 bp | -4.5% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 42.8% | +21 bp | -2.9% |
| PBE | Invesco Biotechnology & Genome ETF | 37.3% | +23 bp | -1.7% |
| BMED | Future Health ETF | 30.9% | +50 bp | -3.8% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 28.7% | +25 bp | +2.9% |
| GNMX | Corgi Genomics & Precision Medicine ETF | 27.6% | 0 bp | -9.1% |
| HELX | Franklin Genomic Advancements ETF | 25.2% | +15 bp | -5.8% |
| GNOM | Global X Genomics & Biotechnology ETF | 22.4% | +15 bp | -7.9% |
| BBP | Virtus LifeSci Biotech Products ETF | 22.2% | +44 bp | -8.8% |
Risk and Returns: BBH vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/3/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
4.8%
ALTAR SCORE™
42nd
PERCENTILE
NEUTRAL
ETFRC RATING
There are 1,399 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. BBH's ALTAR Score™ is approximately -0.2 standard
deviations above the category average. This places BBH in the 42nd percentile
among funds in the category.
Sell-Side Consensus
$226.36
PRICE TARGET
+24.6%
UPSIDE